| Lung Cancer |
1 |
1 |
| Non-Small Cell Lung Cancer |
0 |
0.99 |
| Neoadjuvant Therapy |
0 |
0.98 |
| Platinum |
0 |
0.32 |
| Chemotherapy |
0 |
0.97 |
| Genomic Medicine |
0 |
0.19 |
| Small Cell Lung Cancer |
0 |
0.19 |
| Cancer |
0 |
0.16 |
| Food and Drug Administration (FDA) |
0 |
0.16 |
| Surgery |
0 |
0.16 |
| Tumor |
0 |
0.16 |
| Patient Safety |
0 |
0.13 |
| Peripheral Neuropathy |
0 |
0.12 |
| Constipation |
0 |
0.09 |
| Pneumonia |
0 |
0.09 |
| Adverse Effects |
0 |
0.08 |
| Anaplastic Lymphoma Kinase |
0 |
0.08 |
| Autoimmune Disease |
0 |
0.08 |
| Epidermal Growth Factor Receptor |
0 |
0.08 |
| Fatigue |
0 |
0.08 |
| Hospital |
0 |
0.08 |
| Immunocompromise |
0 |
0.08 |
| Lung |
0 |
0.08 |
| Nausea |
0 |
0.08 |
| Neuropathy |
0 |
0.08 |
| Surgical Complication |
0 |
0.08 |